Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib.

PLoS One · 2017 · PMC5533343 · PMID 28753643

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

only marginally significantno p-value reported

One common variant located 3.2kb 5' of RP3-332B22.1 had a significant interaction P-value, but was only marginally significant in the placebo and darapladib arms.

also in 5,076 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.